{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niacin-ER", "query": { "intervention": "Niacin-ER" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niacin-ER&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T02:35:33.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03370848", "title": "Effects of Psyllium on Niacin Tolerability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Flushing", "Hyperlipidemias", "Dyslipidemias" ], "interventions": [ { "name": "Psyllium", "type": "DIETARY_SUPPLEMENT" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "VA Greater Los Angeles Healthcare System", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2009-03", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370848" }, { "nct_id": "NCT02322203", "title": "Effects of Niacin Therapy on Lipoprotein Composition and Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Niacin Extended Release", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 22, "start_date": "2015-03-25", "completion_date": "2019-07-23", "has_results": true, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02322203" }, { "nct_id": "NCT02624700", "title": "2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "Experimental Arm A: Pemetrexed", "type": "DRUG" }, { "name": "Experimental Arm A: Sorafenib", "type": "DRUG" }, { "name": "Experimental Arm B: Pemetrexed", "type": "DRUG" }, { "name": "Experimental Arm B: Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-01-28", "completion_date": "2019-07-10", "has_results": true, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624700" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT00359281", "title": "Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "atorvastatin", "type": "DRUG" }, { "name": "simvastatin", "type": "DRUG" }, { "name": "ezetimibe", "type": "DRUG" }, { "name": "fenofibrate", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "Extended Release Niacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aegerion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 125, "start_date": "2006-03", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00359281" }, { "nct_id": "NCT00071266", "title": "The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intermittent Claudication", "Peripheral Vascular Disease" ], "interventions": [ { "name": "Niacin Extended Release and Lovastatin Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kos Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 870, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-11-02", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071266" }, { "nct_id": "NCT02702492", "title": "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "NHL" ], "interventions": [ { "name": "KPT-9274", "type": "DRUG" }, { "name": "Niacin ER", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-06-08", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702492" }, { "nct_id": "NCT01426438", "title": "Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Niacin", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2011-11", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-02-03", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01426438" }, { "nct_id": "NCT00300365", "title": "Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metabolic Syndrome" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Niacin ER", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 38, "start_date": "2005-11", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2017-07-28", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300365" }, { "nct_id": "NCT01194869", "title": "Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2010-06", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-09-10T02:35:33.162Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194869" } ] }